In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children’s ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients.

The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.

• Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.

• Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.

• Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.
• Addressing Evidence Gaps: Insider insights into the expert panel’s deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.
• The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.

This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.

Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.

In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.

The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.

The discussion highlights:

• How chronic GVHD independently contributes to immune deficits and infection susceptibility.

• Infectious risks associated with FDA-approved therapies for chronic GVHD.

• Common infections in this population and why vigilance matters.

• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.

This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.

Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.

For a deeper dive, explore Dr. Cheng’s many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.

In this episode of ASTCT Talks, host Christina Ferraro, nurse practitioner from the Cleveland Clinic, sits down with Vanessa Kennedy, MD, from Stanford University, to address a critical aspect of survivorship: cognitive health, including issues like brain fog, memory lapses and reduced executive function.

The discussion highlights:

• New ASTCT consensus guidelines on cognitive assessment.

• Practical strategies for operationalizing cognitive screening in busy clinical settings.

• How factors like anxiety, depression, sleep and polypharmacy influence cognition — and why addressing these is critical.

• Emerging interventions, from cognitive rehabilitation to surprisingly effective options like jigsaw puzzles.

This episode offers actionable insights into supporting cognitive function and quality of life in survivorship care.

In this episode of ASTCT’s Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.

From the groundbreaking ZUMA-1 trial to today’s expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation.

This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.

In this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG.

Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies, with a focus on ciltacabtagene autoleucel and idecabtagene vicleucel.

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. 

Featuring Brooke Adams, PharmD, BCOP 

Natalie Brumwell, PharmD, BCOP 

Bryant A. Clemons, PharmD, BCOP 

In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors.

The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky’s Markey Cancer Center in Lexington, Kentucky. 

The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses.

Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. 

Reference 

FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation.

From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk.

As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler is joined by psychiatrist and physician-scientist Dr. Hermioni Amonoo to explore the psychological complexities faced by patients undergoing stem cell transplantation and living with chronic GVHD. Drawing from her research and clinical experience, Dr. Amonoo introduces a biobehavioral framework that integrates biological, psychological and social factors.

This episode offers practical insights and compassionate strategies for improving psychological well-being in transplant patients, highlighting the importance of interdisciplinary care.

For more information, read the article “A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease” by Lahijani et al. shared in a September 2024 GVHD Supplement collection by the journal.